Search Within

Stephen D Nimer

  1. "Myeloma"
Formats
  1. Meeting Abstract (22)
  2. Journal Article (8)
  3. Book Section (1)
Groups
  1. Center for Hematologic Malignancies (31)
  2. Department of Medicine (31)
  3. Hematologic Malignancies, Division of (31)
  4. Myeloma (31)
  5. Survivorship Research (15)
  6. Bone Marrow Transplant (14)

More Groups

People
  1. Hani Hassoun (31)
  2. Raymond Comenzo (22)
  3. Adam Cohen (15)
  4. Lilian Reich (15)
  5. Martin Fleisher (15)
  6. Heather Landau (14)

More People

Years
  1. 2012 (1)
  2. 2011 (1)
  3. 2010 (3)
  4. 2009 (6)
  5. 2008 (5)
  6. 2007 (3)

More Years

Publications
  1. Blood (18)
  2. Amyloid (3)
  3. Bone Marrow Transplantation (2)
  4. British Journal of Haematology (2)
  5. Journal of Clinical Oncology (2)
  6. Clinical Lymphoma and Myeloma (1)

More Publications

Publishers
  1. American Society of Hematology (18)
  2. Taylor & Francis Group (4)
  3. Nature Publishing Group (3)
  4. American Society of Clinical Oncology (2)
  5. John Wiley & Sons (2)
  6. CRC Press/Taylor & Francis Group (1)

More Publishers

Results (31)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Risk-adapted melphalan (MEL) with stem cell transplant (SCT) and adjuvant dexamethasone (D)+/- thalidomide (T) for AL patients achieves low treatment-related mortality (TRM) and high hematologic response rates
    Meeting Abstract

    Cohen, A. D.; Zhou, P.; Reich, L.; Hassoun, H.; Teruya-Feldstein, J.; Filippa, D. A.; Clark, B.; Stubblefield, M.; Fleisher, M.; Nimer, S. D.; more...
    Amyloid (2006)

    Fulltext@MSK | Save
  • Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: Therapeutic implications
    Journal Article

    Chang, D. H.; Liu, N.; Klimek, V.; Hassoun, H.; Mazumder, A.; Nimer, S. D.; Jagannath, S.; Dhodapkar, M. V.
    Blood (2006)

    Fulltext@MSK | Save
  • Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
    Journal Article

    Hassoun, H.; Reich, L.; Klimek, V. M.; Dhodapkar, M.; Cohen, A.; Kewalramani, T.; Zimman, R.; Drake, L.; Riedel, E. R.; Hedvat, C. V.; more...
    British Journal of Haematology (2006)

    Fulltext@MSK | Save
  • Results of a phase I/II trial adding carmustine (300mg/m 2) to melphalan (200mg/m 2) in multiple myeloma patients undergoing autologous stem cell transplantation
    Journal Article

    Comenzo, R. L.; Hassoun, H.; Kewalramani, T.; Klimek, V.; Dhodapkar, M.; Reich, L.; Teruya-Feldstein, J.; Fleisher, M.; Filippa, D.; Nimer, S. D.
    Leukemia (2006)

    Fulltext@MSK | Save
  • The serum free light chain ratio after one or two cycles of treatment is highly predictive of the magnitude of final response in patients undergoing initial treatment for multiple myeloma
    Meeting Abstract

    Hassoun, H.; Reich, L.; Klimek, V. M.; Dhodapkar, M.; Cohen, A.; Kewalramani, T.; Riedel, E. R.; Hedvat, C. V.; Teruya-Feldstein, J.; Filippa, D. A.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Risk-adapted dosing of melphalan for systemic AL amyloidosis (AL) lowers treatment-related mortality: Early death but not post-3 month survival is linked to cardiac involvement
    Meeting Abstract

    Comenzo, R. L.; Zhou, P.; Hassoun, H.; Kewalramani, T.; Klimek, V.; Cohen, A. D.; Ferrand, S. K.; Dhodapkar, M.; Feldstein, J. T.; Fleisher, M.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Adjuvant dexamethasone (D)+/- thalidomide (T) improves hematologic and organ responses after risk-adapted high-dose melphalan with autologous stem cell transplant (SCT) for patients with systemic AL amyloidosis (AL)
    Meeting Abstract

    Cohen, A. D.; Zhou, P.; Reich, L.; Hassoun, H.; Teruya-Feldstein, J.; Filippa, D. A.; Fleisher, M.; Nimer, S. D.; Comenzo, R. L.
    Blood (2005)

    Fulltext@MSK | Save
  • Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: Report of a phase II trial
    Journal Article

    Gupta, S.; Zhou, P.; Hassoun, H.; Kewalramani, T.; Reich, L.; Costello, S.; Drake, L.; Klimek, V.; Dhodapkar, M.; Teruya-Feldstein, J.; more...
    Bone Marrow Transplantation (2005)

    Fulltext@MSK | Save
  • Doxorubicin and dexamethasone followed by thalidomide and dexamethasone (AD-TD) as initial therapy for symptomatic patients with multiple myeloma
    Meeting Abstract

    Hassoun, H.; Reich, L.; Klimek, V. M.; Kewalramani, T.; Dhodapkar, M.; Drake, L.; Zimman, R.; Hedvat, C. V.; Teruya-Feldstein, J.; Fleisher, M.; more...
    Blood (2004)

    Fulltext@MSK | Save
  • A phase II study of stem cell mobilization with IV melphalan (60 mg/M-2) + G-CSF in multiple myeloma
    Meeting Abstract

    Gupta, S.; Costello, S.; Zhou, P.; Reich, L.; Hassoun, H.; Klimek, V.; Kewalramani, T.; Dhodapkar, M.; Fleisher, M.; Hedvat, C.; more...
    Blood (2003)

    Fulltext@MSK | Save